natgillin/translations-raw huggingface dataset:
According to the present invention there is provided a crystalline hydrated form of the Agent having an X-ray powder diffraction pattern substantially as shown in FIG. 
Kristalinični hidratizirani oblik prema Zahtjevu 1, naznačen time da je njegov pripadni difraktogram X-zraka praškastog oblika spoja prikazan na Slici 1.
Process according to any of claims 1 to 12, characterized in that during step d), said acid(s) of step b) are added, in one or more steps, preferably in one step, to said GNCC. 
Vodena suspenzija prema bilo kojem od zahtjeva 1 do 11, naznačena time da se tijekom koraka d), navedena kiselina(e) iz koraka b) dodaje, u jednom ili više koraka, poželjno u jednom koraku, u navedeni GNCC.
separating the A9-tetrahydrocannabinol from the resulting phase containing the A9-tetrahydrocannabinol; and 
razdvajanje alkoholno-kaustične faze koja sadrži trans-(-)-A9-tetrahidrokanabinol ili trans-(+)-A9-tetrahidrokanabinol od prve organske faze;
In other words, in the equation calculating the amount of the resource of control information, a reduction in the amount of the resource of data signals (i.e., MSCPUSCH-retransmission•NSymbPUSCH-retransmission) on retransmission results in a reduction in the amount of the resource of control information, which leads to the degradation of reception quality of control information. 
Postupak prijenosa za prijenos kontrolne informacije u pluralitetu slojeva, postupak sadržeći: određivanje količine resursa kontrolne informacije u pluralitetu slojeva; 1 prijenos kontrolne informacije na temelju količine resursa kontrolne informacije, naznačeno time da je količina resursa Qowso+cwsr kontrolne informacije određena jednadžbom 1: r t
Pharmaceutical composition according to any one of Claims 8 to 12, characterized in that the said composition contains a stereoisomer or an enantiomer of the compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, or a mixture thereof. 
Farmaceutski sastav prema bilo kojem od zahtjeva 15 do 19, naznačen time, da navedeni sastav sadrži stereoizomer ili enantiomer od spoja formule (I), ili njegovu farmaceutski prihvatljivu sol, ili njegov ester, ili mješavinu od navedenoga.
The compound according to claim 5, wherein the disorder is selected from chronic and acute pain disorders. 
Spoj ili njegova farmaceutski prihvatljiva sol prema patentnom zahtjevu 6, naznačeni time da je poremećaj odabran između kroničnih i akutnih poremećaja boli.
R′″ is selected from the group consisting of hydroxy, alkoxy, substituted alkoxy, acyloxy, cycloalkoxy, substituted cycloalkoxy, aryloxy, substituted aryloxy, heteroaryloxy, substituted heteroaryloxy, aryl, and —S(O)n—R10 wherein R10 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl and n is zero, one or two; 
R"' je odabran iz skupine koja sadrži hidroksi, alkoksi, supstituirani alkoksi, aciloksi, cikloalkoksi, supstituirani cikloalkoksi, ariloksi, supstituirani ariloksi, heteroariloksi, supstituirani heteroariloksi, aril, -S(O)n-R10 pri čemu R10 je odabran iz skupine koja sadrži alkil, supstituirani alkil, cikloalkil, supstituirani cikloalkil, aril, supstituirani aril, heteroaril i supstituirani heteroaril i n je nula, jedan ili dva;
The conjugate of claim 11 wherein the mPEG is a glycerol-branched. 
Konjugat u skladu s patentnim zahtjevom 11, gdje mPEG je razgranat glicerolom.
then converting the compound 15 to the compound of Formula I. 
(vi) zatim konverziju spoja 15 do spoja formule I.
The lithium oxygen battery according to claim 7, wherein said porous cathode current collector comprises a porous material selected from the group comprising carbon paper, reticulated vitreous carbon, reticulated vitreous carbon coated with conductive carbon black, mesoporous carbons, activated carbons, nanostructured carbons and combinations thereof. The lithium oxygen battery of claim 1, further comprising two electrical contacts. 
Litij kisik baterija iz bilo kojeg od patentnih zahtjeva 1 do 6, koja dalje sadrži porozni katodni strujni kolektor (9) gdje, poželjno, navedeni porozni katodni strujni kolektor (9) sadrži porozni materijal odabran iz grupe koja sadrži ugljikov papir, mrežasti stakleni ugljik, mrežasti stakleni ugljik presvučen provodnom čađom, mezoporozne ugljike, aktivirane ugljike, nanostrukturirane ugljike i njihove kombinacije.
A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof 
PATENTNI ZAHTJEVI Spoj predstavljen sljedećom općom formulom (I) ili njegova farmakološki prikladna sol
A compound according to claim 1 of formula (Id): wherein 
Spoj u skladu sa zahtjevom 1, naznačen time, da je formule (Id): gdje
The assembly 12 is fitted on a last and inserted in the mold, placing the insole 16 in contact with the breathable element 21. 
Sklop 12 se postavlja na tabanicu cipele i umeće u kalup, a unutarnji potplat 16 se postavlja tako da dodiruje prozračni element 21.
A method for the preparation of the agomelatine hydrochloride hydrate according to claim 1 or 2, wherein agomelatine is reacted with HCl in an aqueous organic solvent to produce the agomelatine hydrochloride hydrate. 
Postupak za pripremu agomelatin hidroklorid hidrata u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da agomelatin reagira s HCI u vodenom organskom otapalu, čime se dobiva agomelatin hidroklorid hidrat.
Ra and Rb are independently hydrogen or C1-3alkyl; or, when Ra and Rb are each other than hydrogen, Ra and Rb are optionally taken together with the nitrogen atom to which they are both attached to form a five to seven membered monocyclic ring; and pharmaceutically acceptable enantiomers, diastereomers, racemates, and salts thereof. 
R> dušikom na koji su oba spojeni da oblikuju pet do sedam člani monociklički prsten; i njihovi farmaceutski prihvatljivi enantiomeri, diastereomeri, racemati i soli.
providing a compound having the structure 
osiguravanju spoja sa strukturom [image]
A compound of claim 1, or a pharmaceutically acceptable salt thereof, for use according to claim 15 wherein the inflammatory bowel disease is ulcerative colitis. 
Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 15, naznačen time što je upalna crijevna bolest ulcerozni kolitis.
overloading the anion exchange membrane such that at least one contaminant remains bound to the membrane while the polypeptide of interest is primarily in the effluent; 
preopterećenja membrane za anionsku izmjenu na udarnu gustoću od 1000 do 5000 g/L tako da najmanje jedan kontaminant ostaje vezan na membranu dok je željeno protutijelo prvenstveno u efluentu;
In a further embodiment, the reaction temperature is about 85-87° C. In a further embodiment, the reaction time is from about 5 to about 7 hours. 
Postupak u skladu s patentnim zahtjevom 4, naznačen time što je temperatura reakcije otprilike 80 *C do otprilike 87 *C.
The apparatus of claim 2, wherein the controller is operable to control the volume of each of the discrete samples. 
Uređaj prema bilo kojem od gornjih zahtjeva, naznačen time da korisnik može birati volumen svakog od odvojenih uzoraka.
If the laser radiation is not absorbed by the thickness of a pharmaceutical vial closure or plunger it may pass through and affect the contents of the vial or syringe. 
Ako se zračenje lasera ne apsorbira u debljini zatvarača farmaceutske bočice ili klipa, ono može proći skroz i djelovati na sadržaj bočice ili šprice.
Another embodiment of the invention relates to compounds of Formula (I) as defined above wherein n, Y and R3-R7 are as defined above, and both R1 and R2 are hydrogen or one is hydrogen and the other is methyl, ethyl, propyl, tert-butyl, optionally substituted with hydroxy or fluorine, C3-C6 cycloalkyl, optionally substituted with hydroxy or fluorine. 
Spoj formule (I) prema patentnim zahtjevima 1 ili 2 naznačeno time da oba R' i R jesu vodik ili jedan jest vodik a drugi je metil, etil, propil, fert-butil, koji može biti supstituiran s hidroksi ili fluorom, C3-Cg cikloalkil, koji može biti supstituiran s hidroksi ili fluorom.
The solid oral extended release pharmaceutical dosage form of item 68, wherein the composition comprises at least about 80 % (by wt) polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema zahtjevu 1, naznačen time da pripravak sadrži najmanje oko 80 % (težinski) polietilen oksida koji ima, prema reološkim mjerenjima, približnu molekularnu težinu od najmanje 1,000,000.
The method proposed in patent application, U.S. Ser. No. 10/615,230, promotes the formation of shear vibrations in the extraction zone. 
Postupak predložen u patentnoj prijavi U.S. 10/615,230, predstavlja stvaranje poprečnih vibracija u zoni ekstrakcije.
Transmission stage 5, at the output of first circuit section 1a, receives outputs OUT1a, OUT2a, OUT3a, OUT4a of demultiplexer circuit 12a via the interposition of a second optoisolator 17, and controls four respective beacons. 
Podsklop prijenosa 5, kod izlaza prve sekcije komunikacijskih krugova la, prima izlaze OUT1a, OUT2a, OUT3a, OUT4a demultipleksnog komunikacijskog kruga 12a putem umetanja drugog optoizolatora 17 i upravlja s četiri odnosne balize.
Compound 1 for use in the treatment of diabetes, wherein the compound is administered to the same patient every 2nd day or less frequently and, on average, during a period of time of at least 1 month, 6 months or 1 year, said compound is not administered more frequently to the same patient. 
Spoj prema patentnom zahtjevu 1, za uporabu u tretmanu dijabetesa, naznačeno time da je spoj primijenjen na istog pacijenta svaki drugi dan, ili rjeđe, 1, u prosjeku, tijekom vremenskog perioda od najmanje 1 mjeseca, 6 mjeseci ili 1 godine, navedeni spoj nije primjenjen češće na istog pacijenta.
(BL) The Compound of Paragraph (BK) where R4 is methyl. 
Spoj prema patentnom zahtjevu 1, naznačen time što je R* jednako vodik, R* je metil, R!
culturing mesenchymal stem cells in the medium to dedifferentiate the stem cells into induced pluripotent stem cells; and 
dediferenciranje mezenhimalnih matičnih stanica u inducirane pluripotentne matične stanice u mediju; i
In another preferred embodiment of the invention, the neurological disorder to be treated or diagnosed with the VLP of the invention is Parkinson's disease. 
Virusu slična čestica (VLP) za uporabu sukladno barem jednom od gore navedenih patentnih zahtjeva, gdje je neurološki poremećaj Parkinsonova bolest.
By means of said gluing of 11 boards, a block of wood according to the invention resulted having a height of 154 mm. 
Navedenim lijepljenjem 11 ploča stvoren je blok od drva koji ima visinu od 154 mm.
MRI contrast agents which can be used include: gadolinium, manganese, iron, europium, copper, nickel, chrome, prasodymium, dysprosium or holmium or their compounds, but also the negative MRI contrast agents such as perfluorocarbone, as well as isotopes such as such as F-19, H-1, P-31, Na-19 for MRI spectroscopy. 
Derivati peptida GLP-I u skladu s prethodnim patentnim zahtjevima, naznačeni time što kontrastni medij za MRT je gadolinij, mangan, željezo, europij, bakar, nikal, krom, praseodimij, disprozij ili holmij, ili njihovi spojevi, ili perfluorugljik, ili F-19, H-1, P-31, Na-19.
A compound of Formula I 
Spoj formule I s
The compound according to claim 9 or a pharmacologically acceptable salt thereof, or a solvate or hydrate thereof, wherein in the formula (I), Ar1 is a group selected from the group consisting of B1), B2), B6b), B9c), and B9d): wherein R1 is a hydrogen atom, a hydroxy group, a C1 to C3 alkyl group, a C1 to C3 alkoxy group, or a hydroxy C1 to C4 alkyl group; 
Spoj u skladu sa patentnim zahtjevom 9 ili njegova farmakološki prihvatljiva sol, ili njegov solvat ili hidrat, gdje u formuli (I), Ar1 je grupa odabrana iz grupe koja se sastoji od B1), B2), B6b), B9c), i B9d): [image] gdje R1 je atom vodika, hidroksi grupa, C1 do C3 alkil grupa, C1 do C3 alkoksi grupa, ili hidroksi C1 do C4 alkil grupa;
The molecular complex according to claim 1 or claim 2, the composition according to claim 3 or claim 4, or the pharmaceutical composition according to any one of claims 5 to 6 for use in the treatment and/or prevention of disease states associated with osteoporosis, hypercalcemia, cancer induced bone metastasis, Paget's disease or adjuvant or neoadjuvant cancer therapies. 
Molekularni kompleks prema zahtjevu 1 ili zahtjevu 2, pripravak prema zahtjevu 3 ili zahtjevu 4, ili farmaceutski pripravak prema bilo kojem od zahtjeva 5 do 6 naznačen time da je za uporabu za liječenje i/ili sprječavanje bolesnih stanja povezanih s osteoporozom, hiperkalcemijom, metastazama kostiju izazvanih rakom, Pagetovom bolešću ili adjuvantnim ili neoadjuvantnim terapijama raka.
The polypeptide according to any of the preceding claims, wherein the polypeptide binds to an IL-17A mutant with reduced affinity as compared to binding to the wildtype human IL-17A, wherein the IL-17A mutant comprises one or more mutations of L74A, Y85A, and N88A. 
Polipeptid prema bilo kojem od zahtjeva 1-5, naznačen time da se druga sekvenca aminokiseline može specifično vezati na ljudski IL-17A, IL-17F i IL-17A/F, pri čemu se druga sekvenca aminokiseline veže na L74A, i/ili Y85A i/ili N88A IL-17A mutant sa značajno smanjenim afinitetom u usporedbi s vezanjem na divlji tip IL-17A sekvence.
adverse events Number of Subjects 
Broj štetnih događaja/2
Use of a device for subjecting biomass to pyrolysis as claimed in any of the foregoing claims, wherein an at least more or less vertical baffle is situated in the reactor space which connects to the upper wall of the reactor space, whereby the flow from the mixer, comprising a mixture of pyrolysis gas and solid material, and/or the part-flows of pyrolysis gas and solid material can only reach respectively the first discharge and the second discharge by passing over the lower edge of the baffle. 
Upotreba uređaja za podvrgavanje biomase pirolizi prema bilo kojem od prethodnih zahtjeva, naznačena time što se u reaktorskom prostoru nalazi najmanje više ili manje okomita pregrada koja se spaja na gornju stjenku reaktorskog prostora, pri čemu struja iz miješalice, koja sadrži mješavinu plina za pirolizu i krutog materijala, i/ili dijelovi strujanja plina za pirolizu i čvrstog materijala mogu samo doseći odgovarajući prvi ispust 1 drugi ispust prolazom preko donjeg ruba pregrade.
System according to claim 4, wherein the magnetic part is mounted radially in comb-arrangement around said rotation axis and the winding is arranged in comb-arrangement between the magnets, in interdigitated manner. 
Sustav prema patentnom zahtjevu 6, naznačen time da je magnetni dio (36) montiran radijalno u rasporedu češljeva oko navedene osi rotacije, a namotaj je postavljen u rasporedu češljeva između magneta na isprepleteni način.
The nucleic acid molecule of claim 14, wherein the E3 sequence corresponds to (a) residues 1-65 of SEQ ID NO:20, or (b) a variant thereof having at least 80% sequence identity to residues 1-65 of SEQ ID NO:20, wherein residues 62-65 are RSKR (SEQ ID NO: 27), and the variant is capable of being incorporated into a pseudotyped viral envelope. 
Molekula nukleinske kiseline prema zahtjevu 14, naznačena time da E3 sekvenca odgovara (a) ostatcima 1-65 iz SEQ ID NO:20, ili (b) njihovoj varijanti koja ima barem 80% identičnosti sekvence sa ostatcima 1-65 iz SEQ ID NO:20, pri čemu ostatci 62-65 su RSKR (SEQ ID NO: 27), a varijanta se može ugraditi u pseudotipiziranu ovojnicu virusa.
The transdermal therapeutic system according to claim 14, wherein the Gestodene or ester thereof is present in a dose of from 1 to 3 mg. 
Transdermalni terapeutski sustav u skladu sa zahtjevom 14, naznačen time, da je Gestoden ili njegov ester prisutan u dozi od 1 do 3 mg.
The oligonucleotide decoy of claim 2, comprising a sequence that is at least 95% identical with SEQ ID NO:33. 
sekvencu koja obuhvaća barem 85% identiteta sekvence od SEQ ID NO:42 i sadrži jedno ili više mjesta spajanja faktora transkripcije.
A host cell comprising; 
Stanica domaćin koja obuhvaća;
The composition of any one of claims 1-4, wherein X- is selected from the group consisting of the anion of a suitable BrØnsted acid, a hydrogen halide, a carboxylic acid, a sulfonic acid, a sulfuric acid, a phosphoric acid, chloride, bromide, iodide, fluoride, bisulfate, tartrate, nitrate, citrate, bitartrate, carbonate, phosphate, malate, maleate, fumarate sulfonate, methylsulfonate, formate, carboxylate, sulfate, methylsulfate and succinate. The composition of any one of claims 1-5, wherein R1 is C1-4 aliphatic and R2 is lower alkyl; 
Farmaceutski pripravak ili spoj za primjenu prema zahtjevu 3, naznačen time da je X- klorid, bromid, jodid, fluorid, bisulfat, tartrat, nitrat, citrat, bitartrat, karbonat, fosfat, malat, maleat, fumarat sulfonat, metisulfonat, format, karboksilat, sulfat, metilsulfat ili sukcinat. Farmaceutski pripravak ili spoj za primjenu prema zahtjevu 5, naznačen time da je X- bromid. Farmaceutski pripravak prema zahtjevu 1, ili spoj za primjenu prema zahtjevu 2, naznačen time da je R1 C1-4 alifatski a R2 je niži alkil.
wherein X,R and R′ are as defined above. 
(XII) u kojem su X, R i R' definirani gore.
A combination of lipophilic extracts of Zingiber officinale and Echinacea angustifolia for use in the treatment of itching; peripheral pain; superficial or deep inflammatory and painful conditions; pain connected with muscular spasms; herpes pain; radiodermatitis induced by oncological radiotherapy, with or without fungal or bacterial infections; oedema and irritative skin conditions, including those due to excessive exposure to sunlight. 
PATENTNI ZAHTJEVI Kombinacija lipofilnih ekstrakata Zingiber officinale i Echinacea angustifolia za upotrebu u liječenju svrbeži, periferne boli, površinskih ili dubokih upala i bolnih stanja, boli povezanih s mišićnim spazmama, boli urokovanih herpesom, radiodermatitisa induciranog onkološkom radioterapijom sa ili bez gljivičnih ili bakterijskih infekcija, edema ili iritativnih stanja kože uključujući one od pretjeranog izlaganja sunčevu svijetlu.
a prolonged serum half-life compared to an antibody molecule composition of the same antibody molecule isolated from NM-F) when expressed therein; and/or an amount of G2 structures on the total carbohydrate structures or on the carbohydrate structures at one particular glycosylation site of the antibody molecule of said antibody molecules in said antibody molecule composition which is at least 50% higher compared to the same amount of antibody molecules in at least one antibody molecule composition of the same antibody molecule isolated from CHOdhfr- [ATCC No. 
(1v) produljeni poluvijek u serumu u usporedbi s pripravkom s molekulom protutijela za istu molekulu protutijela izoliranu iz NM-F kada se tamo eksprimira; i/ili (v) količinu G2 struktura na ukupnim ugljikohidratnim strukturama ili na ugljikohidratnim strukturama na nekom određenom mjestu glikoziliranja u molekuli protutijela kod navedenih molekula protutijela u navedenom pripravku s molekulom protutijela koja je najmanje 50% veća u usporedbi s istom količinom molekula protutijela u pripravku s najmanje jednom molekulom protutijela za istu molekula protutijela izoliranu iz ATCC No.
R is a moiety comprising at least one functional group selected from the group consisting of a double bound, halo, cyano, hydroxyl, sulfonyl, aldehyde, carbonyl, carboxyl, ether, ester, carboxamide, amine, hydrazinyl, ammonium, azide and 5- or 6-membered heterocyclic group with the proviso that R is not allyl; 
R je vrsta koja obuhvaća barem jednu funkcionalnu skupinu izabranu iz grupe koja obuhvaća halo, cijano, hidroksil, sulfonil, aldehid, karbonil, karboksil, eter, ester, karboksamid, amin, hidrazinil, amonij, azid i 5- ili 6-eročlanu heterocikličku skupinu;
comprising a reductive amination reaction between a compound of following formula (VIII): where R1, R2 and R3 are as defined in claim 1, and a compound of following formula (XI): 
GNK, R2 (VIII) gdje Ry, R2 i R3 jesu kao što je definirano u patentnom zahtjevu 1, i spoja sljedeće formule (XI):
an antibody having a heavy chain as shown in SEQ ID NO: 19 and a light chain as shown in SEQ ID NO: 20; 
(i) -antitijelom koje ima teški lanac kao što je prikazano u SEK ID BR: 19 i laki lanac kao što je prikazano u SEK ID BR: 20;
The water soluble taxane derivative according to claim 1, characterized in that in general formula (1-1), R1 is H, R2 is acetyl, and R3 is phenyl; 
2. - Derivat taksana topiv u vodi u skladu s patentnim zahtjevom 1, naznačen time što u općoj formuli (I-1), R' je H, R' je acetil, a R? je fenil;
Borane pyridine complex (8 M; 72 uL) was added and stirred for 16 hours. 
Doda se boran-piridinski kompleks (8 M; 72 ml), te miješa 16 sati.
The composite flitch is subsequently sliced to form a sheet of wide wood veneer which may be glued to a substrate or a veneer by means of an adhesive. 
Složeni trupac se nakon toga reže na kriške da bi se oblikovao list širokog drvenog furnira koji se može zalijepiti pomoću ljepila na podlogu ili na furnir.
bypass valves provided in said medium circulating passage and respectively arranged for said center mechanisms between a point where said medium supplying passages are connected to said medium circulating passage and a point where said medium returning passages are connected to said medium circulating passage, said bypass valves for opening and closing said medium circulating passage; 
premosni ventili (18, 48) predviđeni u navedenom središnjem cirkulacijskom prolazu i odgovarajuće postavljeni za nevedene središnje mehanizme između točke gdje su navedeni središnji opskrbni prolazi povezani s navedenim središnjim cirkulacijskim prolazom i točke gdje su navedeni središnji povratni prolazi povezani s navedenim središnjim cirkulacijskim prolazom, navedeni premosni ventili za otvaranje i zatvaranje navedenog središnjeg cirkulacijskog prolaza;
The solution was filtered and concentrated in vacuo. 
Otopina se flitrira se i koncentrira in vacuo.
The medicament for use according to any one of claim 1 or claims 3-8, wherein the medicament is a pharmaceutical composition comprising 40 mg/ml glatiramer acetate. 
Lijek za uporabu prema bilo kojem od patentnog zahtjeva 1 ili patentnih zahtjeva 3-8, naznačen time, da lijek jest farmaceutski sastav koji sadrži 40 mg/ml glatiramer acetata.
The long term storage stable non-aqueous liquid bendamustine-containing composition of claim 1, wherein the antioxidant is selected from the group consisting of thioglycerol, monothioglycerol, lipoic acid, propyl gallate, methionine, cysteine, metabisulfites, sodium formaldehyde sulfoxylate, phenol-containing aromatic and aliphatic compounds and dihydrolipoic acid. 
Stabilan pri dugotrajnom skladištenju, nevodeni tekući pripravak s bendamustinom prema bilo kojem od prethodnih zahtjeva, naznačen time, da je antioksidans odabran 1z skupine koju čine tioglicerol, monotioglicerol, lipoinska kiselina, propil galat, metionin, cistein, metabisulfiti, natrijev formaldehid sulfoksilat, aromatski i alifatski spojevi s fenolom i dihidrolipoinska kiselina.
The transdermal delivery device of items 1, 3, or 16 wherein the opioid antagonist is selected from the group consisting of naltrexone, naloxone, nalmephene, diprenorphine, nalmexone, cyprenorphine, alazocine, oxilorphan, cyclophan, nalorphine, nalbuphine, buprenorphine butorphanol, cyclazocine, pentazocine, levallorphan, pharmaceutically acceptable salts thereof, and mixtures thereof. 
Sredstvo za transdermalno davanje prema zahtjevima od 1 do 11, naznačeno time da je opioidni antagonist odabran iz skupine koja se sastoji od naltreksona, naloksona, nalmefena, diprenorfina, nalmeksona, ciprenorfina, alazocina, oksilorfana, ciklofana, nalorfina, nalbufina, buprenorfina, butorfanola, ciklazocina, pentazocina, lovalorfana, njihovih farmaceutski prihvatljivih soli, i njihovih smjesa; i poželjno je naltrekson ili njegova farmaceutski prihvatljiva sol.